| 樊卫飞,王 峻,孟丽娟.厄洛替尼一线治疗老年晚期非小细胞肺癌临床观察[J].肿瘤学杂志,2012,18(3):174-177. |
| 厄洛替尼一线治疗老年晚期非小细胞肺癌临床观察 |
| Clinical Observation of Erlotinib as First Line Treatment for Elderly Patients with Advanced NSCLC |
| 投稿时间：2011-11-23 |
| DOI：10.11735/j.issn.1671-170X.2012.3.B2011453 |
|
 |
| 中文关键词: 厄洛替尼 紫杉醇 肺肿瘤 老年人 一线治疗 药物疗法 |
| 英文关键词:erlotinib paclitaxel lung neoplasms elderly first-line treatment drug therapy |
| 基金项目: |
|
| 摘要点击次数: 2250 |
| 全文下载次数: 906 |
| 中文摘要: |
| 摘 要：［目的］ 比较厄洛替尼靶向与紫杉醇单药一线治疗老年晚期非小细胞肺癌（NSCLC）患者的疗效和不良反应。［方法］ 经病理确诊的老年晚期NSCLC患者62例，厄洛替尼治疗组32例：口服厄洛替尼150mg，1次/d；紫杉醇化疗组30例：紫杉醇75mg／m2，d1、8，静脉滴注，21d为1个周期，2个周期后评价疗效。［结果］ 厄洛替尼治疗组和紫杉醇化疗组近期有效率（RR）分别为28.1％、36.7％，肿瘤控制率（TGCR）分别为71.9％、66.7％，差异无统计学意义(P>0.05)；中位无疾病进展时间（PFS）分别为5.6个月、5.1个月；中位生存期（OS）分别为9.0个月、8.0个月。两组不良反应均可耐受，厄洛替尼治疗组骨髓抑制发生率明显低于紫杉醇化疗组（P<0.05），厄洛替尼治疗组皮疹及腹泻发生率明显较高（P<0.05）。［结论］老年晚期NSCLC患者可从厄洛替尼靶向治疗中获益，不良反应轻微。 |
| 英文摘要: |
| Abstract:［Purpose］ To compare the efficacy and toxicity of erlotinib and pacilitaxel in the first-line treatment for elderly patients with advanced non-small cell lung cancer. ［Methods］Sixty-two elderly cases with histologically or cytologically proven advanced non-small cell lung cancer were divided into two gourps. Thirty-two patients in erlotinib group at a dose of 150mg/d p.o. Thirty patients underwent pacilitaxel intravenously injection at a dose of 75mg/m2.The efficacy was evaluated after 2 cycles (every 21 days as a cycle). ［Results］The response rates(RR) of erlotinib and pacilitaxel group were 28.1％ and 36.7％, respectively; the tumor growth control rates(TGCR) of the 2 groups， 71.9％ and 66.7％, respectively, with no significant difference(P>0.05); median progression-free survival(PFS), 5.6 months and 5.1 months, median overall survival(OS), 9 months and 8 months, respectively. Meanwhile, the toxicity was tolerable in both groups. The occurrence of arrest of bone marrow in erlotinib group was significantly lower than that in paclitaxel group(P<0.05), while the occurrence of rush and diarrhea in erlotinib group was obviously higher than that in the other group(P<0.05). ［Conclusion］ Elderly patients with advanced non-small cell lung cancer can benefit from target treatment of erlotinib with mild toxicity. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|